United States: FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Goodwin Procter LLP

Mondaq

16 Oct 2023 0 shares 1 views

United States: FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Goodwin Procter LLP

Mondaq

Published 16 Oct 2023

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs.

Full Article

United States: FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part I: Underpinnings Of FDA's Proposed Rule - Goodwin Procter LLP

Mondaq 09 Oct 2023

On October 3, 2023, the U.S. Food and Drug Administration (FDA) published its widely anticipated proposed rule on the regulation of..

United States: Regulation Without Legislation: FDA Proposes Rule To Regulate Laboratory Developed Tests And End Historical Enforcement Discretion Policy - Ropes & Gray LLP
Mondaq 04 Oct 2023
United States: FDA Proposes Phased Approach To Regulating Laboratory Developed Tests - Goodwin Procter LLP
Mondaq 02 Oct 2023

United States: FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Goodwin Procter LLP

United States: FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Goodwin Procter LLP

You might like

Related news coverage

United States: FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part I: Underpinnings Of FDA's Proposed Rule - Goodwin Procter LLP

Advertisement